163 related articles for article (PubMed ID: 12369868)
1. Fostriecin: chemistry and biology.
Lewy DS; Gauss CM; Soenen DR; Boger DL
Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
[TBL] [Abstract][Full Text] [Related]
3. Total synthesis of fostriecin (CI-920).
Boger DL; Ichikawa S; Zhong W
J Am Chem Soc; 2001 May; 123(18):4161-7. PubMed ID: 11457179
[TBL] [Abstract][Full Text] [Related]
4. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
[TBL] [Abstract][Full Text] [Related]
5. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
6. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.
Buck SB; Hardouin C; Ichikawa S; Soenen DR; Gauss CM; Hwang I; Swingle MR; Bonness KM; Honkanen RE; Boger DL
J Am Chem Soc; 2003 Dec; 125(51):15694-5. PubMed ID: 14677930
[TBL] [Abstract][Full Text] [Related]
7. Versatile enantiocontrolled synthesis of (+)-fostriecin.
Esumi T; Okamoto N; Hatakeyama S
Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
[TBL] [Abstract][Full Text] [Related]
8. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
Walsh AH; Cheng A; Honkanen RE
FEBS Lett; 1997 Oct; 416(3):230-4. PubMed ID: 9373158
[TBL] [Abstract][Full Text] [Related]
9. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
Weinbrenner C; Baines CP; Liu GS; Armstrong SC; Ganote CE; Walsh AH; Honkanen RE; Cohen MV; Downey JM
Circulation; 1998 Sep; 98(9):899-905. PubMed ID: 9738645
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric total synthesis of (+)-fostriecin.
Reddy YK; Falck JR
Org Lett; 2002 Mar; 4(6):969-71. PubMed ID: 11893198
[TBL] [Abstract][Full Text] [Related]
11. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
[TBL] [Abstract][Full Text] [Related]
12. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
Hastie CJ; Cohen PT
FEBS Lett; 1998 Jul; 431(3):357-61. PubMed ID: 9714542
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.
Theobald B; Bonness K; Musiyenko A; Andrews JF; Urban G; Huang X; Dean NM; Honkanen RE
Mol Cancer Res; 2013 Aug; 11(8):845-55. PubMed ID: 23671329
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of the C1-C12 fragment of fostriecin.
Cossy J; Pradaux F; BouzBouz S
Org Lett; 2001 Jul; 3(14):2233-5. PubMed ID: 11440587
[TBL] [Abstract][Full Text] [Related]
15. The predicted beta12-beta13 loop is important for inhibition of PP2Acalpha by the antitumor drug fostriecin.
Evans DR; Simon JA
FEBS Lett; 2001 Jun; 498(1):110-5. PubMed ID: 11389908
[TBL] [Abstract][Full Text] [Related]
16. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
Bialy L; Waldmann H
Chemistry; 2004 Jun; 10(11):2759-80. PubMed ID: 15195307
[TBL] [Abstract][Full Text] [Related]
17. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of type II topoisomerase by fostriecin.
Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
[TBL] [Abstract][Full Text] [Related]
19. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization.
Ho DT; Roberge M
Carcinogenesis; 1996 May; 17(5):967-72. PubMed ID: 8640945
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of cytostatin analogues.
Bialy L; Waldmann H
Chem Commun (Camb); 2003 Aug; (15):1872-3. PubMed ID: 12932009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
